Diabetes mellitus is a global public health issue affecting 536.6 million people worldwide
in 2021 [
[1]
]. Previous studies have established clear epidemiological links between diabetes mellitus
and various co-morbidities, including colorectal cancers (CRC) [
- Sun H.
- Saeedi P.
- Karuranga S.
- Pinkepank M.
- Ogurtsova K.
- Duncan B.B.
- et al.
IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates
for 2021 and projections for 2045.
Diabetes Res Clin Pract. 2022; 183 (Epub 20211206PubMed PMID: 34879977)109119https://doi.org/10.1016/j.diabres.2021.109119
2
,
3
,
- Vigneri P.
- Frasca F.
- Sciacca L.
- Pandini G.
- Vigneri R.
Diabetes and cancer.
Endocr Relat Cancer. 2009; 16 (Epub 20090720PubMed PMID: 19620249): 1103-1123https://doi.org/10.1677/ERC-09-0087
4
]. Several groups investigated the effects of anti-diabetic medications on the risk
of CRC. However, the effects of newer agents, especially dipeptidyl peptidase 4 inhibitors
(DPP4i) and sodium-glucose co-transporter 2 inhibitors (SGLT2i), received less attention.
To compare the risks of incident CRC amongst DPP4i and SGLT2i users, we conducted
the present study using a large territory wide cohort in Hong Kong consisting of all
type 2 diabetes mellitus (T2DM) patients on any of the two medication classes.Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to European Journal of Internal MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.Diabetes Res Clin Pract. 2022; 183 (Epub 20211206PubMed PMID: 34879977)109119https://doi.org/10.1016/j.diabres.2021.109119
- Diabetes and cancer: a consensus report.Diabetes Care. 2010; 33: 1674-1685https://doi.org/10.2337/dc10-0666
- Diabetes and cancer.Endocr Relat Cancer. 2009; 16 (Epub 20090720PubMed PMID: 19620249): 1103-1123https://doi.org/10.1677/ERC-09-0087
- Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer.Br J Surg. 2013; 100 (PubMed PMID: 24037561): 1421-1429https://doi.org/10.1002/bjs.9229
- An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus.Curr Opin Endocrinol Diabetes Obes. 2017; 24 (PubMed PMID: 27898586; PubMed Central PMCID: PMCPMC6028052): 73-79https://doi.org/10.1097/MED.0000000000000311
- Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control.Kidney Int. 2014; 85 (Epub 20130925PubMed PMID: 24067431; PubMed Central PMCID: PMCPMC3973038): 962-971https://doi.org/10.1038/ki.2013.356
- Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.Kidney Int. 2018; 93 (Epub 20170830PubMed PMID: 28860019): 231-244https://doi.org/10.1016/j.kint.2017.06.017
- Suppressive effects of the sodiumglucose cotransporter 2 inhibitor tofogliflozin on colorectal tumorigenesis in diabetic and obese mice.Oncol Rep. 2019; 42 (Epub 20191007PubMed PMID: 31638239): 2797-2805https://doi.org/10.3892/or.2019.7357
- Potential use of serum insulin-like growth factor 1 and E-cadherin as biomarkers of colorectal cancer.Colorectal Dis. 2020; 22 (Epub 20201001PubMed PMID: 32929869): 2078-2086https://doi.org/10.1111/codi.15360
- Gender difference in the association of insulin and the insulin-like growth factor axis with colorectal neoplasia.Int J Obes. 2012; 36 (Epub 20110614PubMed PMID: 21673650): 440-447https://doi.org/10.1038/ijo.2011.114
Article info
Publication history
Published online: January 31, 2023
Accepted:
January 25,
2023
Received in revised form:
January 17,
2023
Received:
August 28,
2022
Footnotes
☆Declaration of Competing Interest: None.
☆☆Financial Support: None.
Identification
Copyright
© 2023 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.
